Drug intelligence / Profile preview

PF-07872419

Development stage: Unknown
Lead developer: Pfizer
Modality: Vaccines & Immunotherapeutics
Administration: Intramuscular

Overview

PF-07872419 is an investigational pneumococcal polysaccharide-protein conjugate developed by Pfizer. It serves as a component of an expanded multivalent pneumococcal conjugate vaccine (PCV) candidate, which is currently being evaluated in Phase 3 clinical trials (e.g., Trial ID 2025-523447-35-02). The expanded vaccine aims to broaden the serotype coverage beyond the 20 serotypes included in Prevenar 20 (PCV20) to provide enhanced protection against invasive pneumococcal disease and pneumonia in infants. Like other Pfizer pneumococcal vaccines, this component likely utilizes the CRM197 carrier protein to enhance immunogenicity.

Targets

CPS (Streptococcus pneumoniae capsular polysaccharide)

Beyond the preview

Go deeper on PF-07872419.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PF-07872419.

Explore the full profile